Resverlogix Corp.

Events/Webcasts

Webcasts

Periocically Resverlogix will webcast from selected conferences/events. Active links will be posted here.

On Sept. 25, 2015, Resverlogix’s clinical and scientific teams along with Professor Kausik K. Ray and Dr. Kamyar Kalantar-Zadeh of the BETonMACE clinical steering committee presented a Research & Development Update for apabetalone (RVX-208) in New York City.

The presentation is available via web replay. To access the presentation, please click here: http://services.choruscall.ca/links/resverlogix150929.html

Events - Q1 2016

Resverlogix will be attending several key industry conferences. Not all events offer a presentation opportunity. Please note this list is not exhaustive and subject to change.

Jan. 11-13: Biotech Showcase/JP Morgan. San Francisco, CA.

Feb. 8-9: BIO CEO & Investor Conference. New York, NY.

Feb. 15-18: Cavendish Global Impact Forum. Palm Beach, FL.

Mar. 13-16: 28th Annual ROTH Conference. Orange County, CA.

Mar. 21-22: Alberta Epigenetics Network. Banff, AB.

Mar. 23: The Richmond Club. Toronto, ON.

Resverlogix in the Media

Jan. 20, 2016: Resverlogix featured in the Life Sciences Report: http://www.thelifesciencesreport.com/pub/na/16862 

Sept. 2015: At the 2015 Rodman & Renshaw healthcase conference, Mr. McCaffrey also had the opportunity to speak with Stock News Now (SNN). The video interview can be accessed here: https://www.youtube.com/watch?v=Xwd6fT8xFJw 

Aug. 26, 2015: Resverlogix featured in the Life Sciences Report: Disrupting Treatment of Cardiovascular Disease with Epigenetics: Resverlogix CEO Donald McCaffrey. Access article here: /upload/media_element/218/01/donald-mccaffrey-lsr-interview-8-26-15.pdf

June 25, 2015: Resverlogix’s Dr. Ewelina Kulikowski has written and published an article for the summer 2015 issue of the European Biopharmaceutical Review (EBR) titled, “New Direction.” Access article here: http://www.resverlogix.com/upload/media_element/213/01/ebr_july-15_pp.76-79-resverlogix-corp.pdf 

April 22, 2015: Donald McCaffrey, President & CEO on BNN’s Business Day
 

April 27, 2015- BioCentury: Hepalink gains rights to Resverlogix’s RVX-208 in China. Link here: http://www.biocentury.com/dailynews/company/2015-04-27/hepalink-gains-rights-to-resverlogixs-rvx-208-in-china

April 28, 2015- BioWorld Today: Phase III Starting Soon. Resverlogix getting specific: With potential $400M BET, Hepalink licensing accord, by Randy Osborne. Link here to access the full article.

April 28, 2015- Bloomberg Business: Resverlogix in Discussions to Be Bought, by Eric Lam. Link here: http://www.bloomberg.com/news/articles/2015-04-28/resverlogix-ceo-says-company-in-discussions-to-be-bought

April 28, 2015- BioSpace Breaking News: Resverlogix (RVX.TO) CEO Says It’s in Talks With Suitors, After $100M in Q1 Deals, by Riley McDermid. Link here: http://www.biospace.com/News/with-almost-a-100-million-in-deals-for-q1/374186?source=sm&type=twitter_resverlogix042815

April 28, 2015- Fierce Biotech: Resverlogix gets a $116M China Drug development deal, stokes buyout buzz, by John Carroll. Link here: http://www.fiercebiotech.com/story/resverlogix-gets-116m-china-drug-development-deal-stokes-buyout-buzz/2015-04-28

April 28, 2015 - GEN News Highlights: Hepalink Buys China-Area Rights to Resverlogix's CV Candidate for Up-to-$441.5M Link here: http://www.genengnews.com/gen-news-highlights/hepalink-buys-china-area-rights-to-resverlogix-s-cv-candidate-for-up-to-441-5m/81251205/

To arrange a meeting with senior management, please contact Sarah Zapotichny, Director of Investor Relations & Corporate Communications at sarah@resverlogix.com